Locus Biosciences says the US$35m in funding it has raised from a mix of old and new investors is further validation of its novel approach to treating bacterial diseases.
Locus Biosciences has entered a credit facility of up to US$25m with Hercules Capital, which it says will support the expansion of its precision engineered bacteriophage discovery platform engine and in-house manufacturing capacity.